James Hopkins, MD
Cardiovascular Disease · Newark, DENPI 1912900630
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,399 of the $7,196 with a category attached, or 61.1%. 19 manufacturers reported payments, led by Edwards Lifesciences at 33.0% of the total. 2025 is the largest year on record at $3,651, 2.8 times the $1,309 reported in 2019.
Across 112 payments — averaging $64.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Abbott$2K
- E.r. Squibb & Sons, L.L.C.$689
- Medtronic$652
- Boston Scientific$519
- Abiomed$209
- plus $884 from 13 others
Across 51 payments — averaging $1414.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$72K
What the payments were for
- Grants$661%
- Travel & lodging$2,68437%
- Food & beverage$4,39961%
- Education$40%
- Entertainment$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 18 | $2,375 |
| Abbott | 12 | $1,868 |
| E.r. Squibb & Sons, L.L.C. | 13 | $689 |
| Medtronic(2 entities) | 11 | $652 |
| Boston Scientific | 13 | $519 |
| Abiomed | 3 | $209 |
| Heartflow, Inc. | 2 | $174 |
| AstraZeneca | 9 | $157 |
| Johnson & Johnson | 11 | $152 |
| Novartis | 5 | $77 |
| Organogenesis Inc. | 2 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $58 |
| Pfizer | 2 | $53 |
| Hitachi Healthcare Americas Corp. | 1 | $43 |
| Biotronik Inc. | 2 | $35 |
| Amgen | 2 | $26 |
| W. L. Gore & Associates, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $16 |
| Smith+Nephew | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVOQUE$1,450
- TRICLIP$1,439
- PASCAL$389
- CoreValve Evolut$161
- FFRct$150
- Impella$142
- COREVALVE EVOLUT R$134
- Edwards SAPIEN 3 Transcatheter Heart Valve$126
- ELIQUIS$121
- GENERAL - STENTS$111
- GENERAL - STRUCTURAL HEART$107
How this compares
$7,196 in reported general payments places this provider in the 70th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 195 | $258,388 |
| XareltoRivaroxaban | 65 | $98,667 |
| Repatha SureclickEvolocumab | 23 | $35,653 |
| FarxigaDapagliflozin Propanediol | 15 | $18,480 |
| Atorvastatin Calcium | 397 | $7,052 |
| Valsartan | 112 | $6,328 |
| Metoprolol Succinate | 322 | $5,899 |
| Losartan Potassium | 181 | $2,680 |
| Rosuvastatin Calcium | 136 | $2,476 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 121 | $2,395 |
| Carvedilol | 159 | $2,351 |
| Ranolazine ErRanolazine | 17 | $2,229 |
| ClopidogrelClopidogrel Bisulfate | 123 | $2,213 |
| Amlodipine Besylate | 219 | $1,854 |
| Lisinopril | 164 | $1,553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $53 | $258,388195 claims |
| Johnson & JohnsonXarelto | $152 | $98,66765 claims |
| AstraZenecaFarxiga | $157 | $18,48015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Newark
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Anthony ClayNewark$37K
- Ashish ParikhNewark$26K
- William WeintraubNewark$24K
- Wen Chi TsaiNewark$20K
- Stephen MengNewark$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.